(0.00%) 5 478.25 points
(-0.02%) 38 812 points
(0.04%) 19 929 points
(0.27%) $80.55
(1.11%) $2.82
(0.10%) $2 331.40
(-0.39%) $29.28
(-0.08%) $970.10
(0.03%) $0.932
(-0.11%) $10.64
(0.08%) $0.788
(-1.86%) $86.80
3 days till quarter result
(tns 2024-06-21)
Expected move: +/- 9.18%
Live Chart Being Loaded With Signals
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development...
Stats | |
---|---|
Šios dienos apimtis | 1.42M |
Vidutinė apimtis | 1.56M |
Rinkos kapitalizacija | 5.10B |
EPS | $-0.200 ( Q1 | 2024-05-02 ) |
Kita pelno data | ( $-0.890 ) 2024-06-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.43 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0300 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-03 | Scott Randal W. | Sell | 800 | Common Stock |
2024-06-03 | Scott Randal W. | Sell | 200 | Common Stock |
2024-06-04 | Scott Randal W. | Sell | 1 500 | Common Stock |
2024-05-16 | Kumar Neil | Buy | 60 667 | Common Stock |
2024-05-16 | Kumar Neil | Sell | 30 748 | Common Stock |
INSIDER POWER |
---|
-25.58 |
Last 100 transactions |
Buy: 1 295 234 | Sell: 2 586 640 |
Tūris Koreliacija
BridgeBio Pharma Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
RRGB | 0.93 |
LPSN | 0.927 |
AMPH | 0.924 |
NARI | 0.919 |
SPTN | 0.919 |
COMM | 0.918 |
CNXC | 0.915 |
SMSI | 0.915 |
QNRX | 0.914 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
MTEK | -0.903 |
KINS | -0.901 |
JVA | -0.896 |
ASMB | -0.896 |
VNOM | -0.892 |
BWMX | -0.89 |
CDRO | -0.888 |
NATL | -0.888 |
ARYD | -0.887 |
FANG | -0.883 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
BridgeBio Pharma Inc Koreliacija - Valiuta/Žaliavos
BridgeBio Pharma Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $9.30M |
Bruto pelnas: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2023 |
Pajamos: | $9.30M |
Bruto pelnas: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2022 |
Pajamos: | $77.65M |
Bruto pelnas: | $74.21M (95.58 %) |
EPS: | $-3.35 |
FY | 2021 |
Pajamos: | $69.72M |
Bruto pelnas: | $66.60M (95.53 %) |
EPS: | $-4.77 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.